Genmab A/S announced that it has entered into an agreement to acquire Merus N.V., a clinical-stage biotechnology company, for USD 97.00 per share in an all-cash deal valued at approximately USD 8.0 billion. The boards of directors of both companies have unanimously approved the transaction, which is expected to close in the first quarter of 2026. The proposed acquisition will add petosemtamab, a late-stage asset with two Breakthrough Therapy Designations currently in Phase 3 development, to Genmab's portfolio. Genmab stated that the transaction is anticipated to be accretive to EBITDA by the end of 2029 and will not impact its financial guidance for the full year 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genmab A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001130313-en) on September 29, 2025, and is solely responsible for the information contained therein.